Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) are the most commonly reported sexually transmitted infections in Canada. Untreated infections are associated with added substantial morbidity that in pregnant persons can have serious implications. The potential to cause downstream sequelae to the birthing parents and their fetus or newborn are of particular concern. There is a pan-Canadian need for guidance on the optimal approach, test, specimen, frequency, and timing for CT and GC screening during pregnancy. A comprehensive and multidisciplinary review of the literature is required to guide policy-makers on important considerations for formulating new guidelines for a national screening strategy.
CADTH conducted a systematic assessment of the clinical effectiveness, safety, cost-effectiveness, perspectives and experiences of pregnant persons, partners, and health care providers regarding the screening of pregnant persons for CT and GC.